Definitive Contract 75A50124C00046
Award Date
9/30/24
Potential Completion Date
12/31/30
Potential Value
$188M
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $282,450,108.67 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation. The contract is for the development and implementation of Cerus's proprietary pathogen reduction technology (PRT) known as the INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, helping to reduce the risk of transfusion-transmitted infections. The...
The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
The Food and Drug Administration (FDA) awarded a $11,106,465 definitive contract to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract, which does not have a set-aside designation, is for the development of an optimized pathogen inactivation process for whole blood. This contract was awarded under a Broad Agency Announcement (BAA) solicitation by the FDA to advance regulatory science and innovation across various...
This federal contract award is for the supply of INTERCEPT Platelet Small Volume Sets by Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $104,256.00, was awarded by the Defense Health Agency, a defense agency within the Department of Defense. The contract is a Firm Fixed Price Purchase Order with a period of performance through September 3, 2024. Cerus Corporation has a history of providing its...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
This is a $199,584.00 firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that specializes in blood safety technologies. The contract is for the supply of INTERCEPT platelet processing sets, which use the company's proprietary INTERCEPT Blood System to inactivate pathogens in blood components. This system plays a crucial role in reducing the risk of transfusion-transmitted infections in blood products used by military and...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...